Goldenwell Biotech, Inc. (GWLL)

OTCMKTS · Delayed Price · Currency is USD
2.900
0.00 (0.00%)
At close: Dec 29, 2025
1,350%
Market Cap287.10M
Revenue (ttm)62.34K
Net Income (ttm)-75.12K
Shares Out99.00M
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume200
Average Volume2,950
Open2.900
Previous Closen/a
Day's Range2.900 - 2.900
52-Week Range0.200 - 10.000
Beta5.43
RSI55.54
Earnings DateMay 8, 2026

About Goldenwell Biotech

Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio. [Read more]

Founded 2019
Country United States
Stock Exchange OTCMKTS
Ticker Symbol GWLL
Full Company Profile

Financial Performance

In 2024, Goldenwell Biotech's revenue was $139, a decrease of -92.43% compared to the previous year's $1,836. Losses were -$131,498, 12.0% more than in 2023.

Financial Statements

News

There is no news available yet.